Free Trial
CVE:COV

Covalon Technologies (COV) Stock Price, News & Analysis

Covalon Technologies logo
C$2.45 +0.05 (+2.08%)
As of 06/19/2025 03:31 PM Eastern

About Covalon Technologies Stock (CVE:COV)

Key Stats

Today's Range
C$2.41
C$2.47
50-Day Range
C$2.25
C$2.80
52-Week Range
C$2.01
C$4.30
Volume
4,100 shs
Average Volume
28,753 shs
Market Capitalization
C$67.13 million
P/E Ratio
28.12
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.

Receive COV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covalon Technologies and its competitors with MarketBeat's FREE daily newsletter.

COV Stock News Headlines

Why the Pentagon has its eye on Utah...
There's a strange bidding war underway in Utah... Smack in the middle of Utah's Black Desert...The U.S. government is holding record land auctions. Why? Because it turns out America has access to a powerful new form of energy – not gas, oil, or uranium – that's buried deep beneath U.S. soil. This abundant new power source is so plentiful... the U.S. Department of Energy says it could fuel the entire U.S. economy uninterrupted for the next 2 million years. If not longer.
Covalon Technologies Ltd.
See More Headlines

COV Stock Analysis - Frequently Asked Questions

Covalon Technologies' stock was trading at C$3.25 at the start of the year. Since then, COV stock has decreased by 24.6% and is now trading at C$2.45.
View the best growth stocks for 2025 here
.

Shares of COV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Covalon Technologies investors own include NIO (NIO), Reliq Health Technologies (RHT), Facedrive (FDVRF), Meta Platforms (META), NVIDIA (NVDA), Ackroo (AKR) and BeWhere (BEW).

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
CVE:COV
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
28.12
Forward P/E Ratio
8.17
P/E Growth
N/A
Net Income
C$2.39 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$27.87 million
Cash Flow
C$0.57 per share
Price / Cash Flow
4.28
Book Value
C$0.90 per share
Price / Book
2.73

Miscellaneous

Free Float
N/A
Market Cap
C$67.13 million
Optionable
Not Optionable
Beta
0.64
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (CVE:COV) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners